This focused series on “The Use of OCT as a Biomarker in Neuro-ophthalmology” is edited by Fiona Costello, Departments of Clinical Neuroscience and Surgery, Cumming School of Medicine, University of Calgary, Canada; and Steffen Hamann, Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Denmark.
Over the past two decades, optical coherence tomography (OCT) has transitioned from being an ocular imaging technology used predominantly in the management of patients with glaucoma and retinal diseases, to an invaluable tool in neuro-ophthalmic practice. As a surrogate marker of neuroaxonal integrity, OCT and recent advancements in OCT-angiography (OCT-A), are now used to diagnose many optic neuropathies, and prognosticate visual recovery over time.
Optical coherence tomography in neuro-ophthalmology: bridging the gap between scientific discovery and clinical practice
Optical coherence tomography in optic disc drusen
Overview of optical coherence tomography in neuro-ophthalmology
Optical coherence tomography use in idiopathic intracranial hypertension
Optical coherence tomography in compressive lesions of the anterior visual pathway
Application of optical coherence tomography in hereditary, toxic and metabolic optic neuropathies
Focal alteration of the intraretinal layers in neurodegenerative disorders
Evaluating visual outcomes using optical coherence tomography (OCT) in pediatric multiple sclerosis and other neuroinflammatory conditions
Optical coherence tomography in ischemic optic neuropathy
Disclosure:
The series “The Use of OCT as a Biomarker in Neuro-ophthalmology” was commissioned by the editorial office, Annals of Eye Science without any sponsorship or funding. Fiona Costello and Steffen Hamann served as the unpaid Guest Editors for the series.